Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasculitic neuropathies: an update.

Kenneth C Gorson1

  • 1Tufts University School of Medicine, Boston, Massachusetts, USA. kengorson@comcast.net

The Neurologist
|January 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Corrigendum to 'Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20' [Journal of the Neurological Sciences, 486 (2026) 125918].

Journal of the neurological sciences·2026
Same author

Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

Journal of the neurological sciences·2026
Same author

Measurement properties of the Inflammatory Rasch-built Overall Disability Scale (I-RODS) in patients with Guillain-Barré syndrome.

Journal of neurology·2026
Same author

Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.

Clinical drug investigation·2023
Same author

CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.

Neurology·2023
Same journal

Artificial Intelligence in the Prehospital Stage of Stroke: Can Virtual Assistants Optimize Triage?

The neurologist·2026
Same journal

Looking Beyond the Midline: An Uncommon Etiology of Internuclear Ophthalmoplegia of Abduction Due to Cerebral Venous Thrombosis.

The neurologist·2026
Same journal

Commentary: Cervical Artery Dissection and Chiropractic Cervical Manipulation: Clarifying Association, Mechanism, and Interpretation.

The neurologist·2026
Same journal

Acute Spinal Cord Infarct Secondary to Fibrocartilaginous Embolism Treated With Tenecteplase.

The neurologist·2026
Same journal

Cervical Artery Dissection and Chiropractic​​​​​.

The neurologist·2026
Same journal

Oromandibular Dyskinesia Associated With Levofloxacin and Responsive to Low-Dose Oral Diazepam: A Case Report.

The neurologist·2026
See all related articles

Systemic vasculitis can cause peripheral neuropathy. Treatment for vasculitic neuropathy, especially nonsystemic vasculitic neuropathy (NSVN), often requires long-term immunosuppression, with cyclophosphamide being a key therapeutic agent.

Area of Science:

  • Neurology
  • Rheumatology
  • Immunology

Background:

  • Systemic vasculitis, a condition affecting blood vessels, can be primary or secondary to other diseases.
  • Peripheral neuropathy is a common complication of systemic vasculitis, resulting from nerve damage.
  • Nonsystemic vasculitic neuropathy (NSVN) is a rare form where neuropathy is the only symptom, diagnosed via nerve biopsy.

Purpose of the Study:

  • To review the diagnostic approaches to vasculitic neuropathy.
  • To summarize current treatment strategies for vasculitic neuropathy, including NSVN.

Main Methods:

  • Review of clinical features, diagnostic tests (including nerve biopsy), and treatment options for vasculitic neuropathy.
  • Analysis of laboratory findings (e.g., elevated ESR, ANCA) and electrodiagnostic studies.

Related Experiment Videos

Main Results:

  • Vasculitic neuropathy often presents as a painful, sensorimotor polyneuropathy.
  • Diagnosis is supported by systemic inflammation markers and electrodiagnostic findings, with nerve biopsy being crucial, especially for NSVN.

Conclusions:

  • Long-term immunosuppressive therapy is generally necessary for vasculitic neuropathy.
  • Standard initial treatment involves prednisone and cyclophosphamide; alternative agents are available for intolerant patients.
  • Evidence for alternative treatments is limited, emphasizing the importance of established protocols.